Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2007

View Archived Issues

Sanofi-aventis reports recent pipeline progress

Novel wound-healing agents disclosed in recent Euticals patent

Recent patents impart novel therapeutics for the treatment of cancer

Promising results for HE-32356 in mouse models of hormone-refractory prostate and breast cancer

Old drug improves learning in a mouse model of Down syndrome

Phase IIb study evaluates ganaxolone for infantile spasms

Symbollon receives German regulatory input on IoGen program

NX-1207 completes long-term follow-up study in BPH

Advisory Committee date set for Provenge review

Acrux and Organon to develop contraceptive sprays

EvoGenix and Vegenics collaborate on VEGF-D antibody therapeutic products

GSK enrolling for prepandemic influenza vaccine clinical trials

Point Therapeutics advances talabostat studies

Insert and R&D sign agreement on second-generation epothilones

Innocoll files IND for CollaRx Bupivacaine Implant

ImmuneRegen to study Viprovex with Tamiflu

Sunesis files IND for Aurora kinase inhibitor SNS-314

Dynavax's novel HBV therapy studied in phase I

Financing at Microbia supports ongoing phase II studies

Pediatric exclusivity granted for Risperdal

Quadramet studied with PSA-TRICOM for hormone-refractory prostate cancer

Bremelanotide shows activity in postmenopausal women with FSAD

Incyclinide shows dose-response relationship in acne

MAP's inhaled migraine treatment demonstrates statistically significant pain relief

New therapeutic agents for HCV infection disclosed in recent patents

Thalidomide Pharmion MAA accepted for review in E.U.

Follistim approved in Japan for new indication

ASAQ fixed-dose formulation now available against malaria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...